Performance evaluation of NeuMoDx 96 system for hepatitis B and C viral load

doi:10.5501/wjv.v12.i4.233

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3475)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

1614

Figures (1-1)

249

Tables (1-4)

301

Sum=2308

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

141

Download

410

Sum=551

Publishing Process of This Article

Item

Count

Browse

175

Download

315

Sum=490

Sep 25, 2023 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Virol. Sep 25, 2023; 12(4): 233-241
Published online Sep 25, 2023. doi: 10.5501/wjv.v12.i4.233

Table 1 Comparison of characteristics between assay 1 and assay 2

Parameter	HBV		HCV
Parameter	Assay 1	Assay 2	Assay 1	Assay 2
Sample volume	550 µL plasma	650 µL plasma	550 µL plasma	650 µL plasma
Turnaround time	Approximately 1.00 h	Approximately 5.00 h	Approximately 1.25 h	Approximately 5.45 h
LOD in IU/mL	8.0	20	8.0	≥ 15
LLOQ as log₁₀ IU/mL	0.9	1.3	0.9	1.5
Linear range quantification as log₁₀ IU/mL	1-9	1.3-8.2	1-9	1.5

HBV: Hepatitis B virus; HCV: Hepatitis C virus; IU: International unit; LLOQ: Lower limit of quantitation; LOD: Limit of detection.

Table 2 Baseline demographic and clinical characteristics of the study population

Characteristic	HBV patient group	HCV patient group
Patients, n	99	87
Sex as M/F ratio	3.34:1.00	1.71:1.00
Age in yr, mean ± SD	44.0 ± 14.6	46.0 ± 14.9
Total bilirubin in mg/dL, median (IQR)	0.83 (0.59-0.83)	0.95 (0.58-2.15)
Direct bilirubin in mg/dL, median (IQR)	0.18 (0.10-0.47)	0.25 (0.10-0.62)
ALT values in IU/mL, median (IQR)	32.5 (23.2-60.1)	33 (17.0-59.7)
AST values in IU/mL, median (IQR)	36 (28.00-62.75)	46 (27.0-99.2)
NeuMoDx viral load as log₁₀ IU/mL, median (IQR)	2.9 (2.0-4.3)	4.9 (4.2-5.4)
COBAS viral load as log₁₀ IU/mL, median (IQR)	3.7 (2.28-4.56)	5.1 (4.07-5.80)

ALT: Alanine transaminase, AST: Aspartate aminotransferase; F: Female; HBV: Hepatitis B virus; HCV: Hepatitis C virus; IQR: Interquartile range; IU: International unit; M: Male; SD: Standard deviation.

Table 3 Comparison of hepatitis B virus viral load results between assay 1 and assay 2

Range of viral load as log₁₀ IU/mL	HBV
Range of viral load as log₁₀ IU/mL	Assay 1, n = 49	Assay 2, n = 49
10¹-10³	n = 25 (51.0%)	n = 19 (38.7%)
10³-10⁶	n = 18 (36.7%)	n = 25 (51.0%)
> 10⁶	n = 6 (12.2%)	n = 5 (10.2%)

HBV: Hepatitis B virus.

Table 4 Comparison of hepatitis C virus viral load results between assay 1 and assay 2

Range of viral load (log₁₀ IU/mL)	HCV
Range of viral load (log₁₀ IU/mL)	Assay 1 (n = 39)	Assay 2 (n = 39)
10¹-10³	n = 4 (10.2%)	n = 2 (5.1%)
10³-10⁶	n = 32 (82.0%)	n = 28 (71.7%)
> 10⁶	n = 3 (7.69%)	n = 9 (23.07%)

HCV: Hepatitis C virus.

Citation: Chooramani G, Samal J, Rani N, Singh G, Agarwal R, Bajpai M, Kumar M, Prasad M, Gupta E. Performance evaluation of NeuMoDx 96 system for hepatitis B and C viral load. World J Virol 2023; 12(4): 233-241
URL: https://www.wjgnet.com/2220-3249/full/v12/i4/233.htm
DOI: https://dx.doi.org/10.5501/wjv.v12.i4.233